Zhang Jian, Zhang Chunning, Jiang Huali, Jiang Hualong, Yuan Yawei
Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Guangzhou, China.
The First Tumor Department, Maoming People's Hospital, Maoming, China.
Front Oncol. 2021 May 31;11:647221. doi: 10.3389/fonc.2021.647221. eCollection 2021.
Lysine acetylation and deacetylation are posttranslational modifications that are able to link extracellular signals to intracellular responses. However, knowledge regarding the status of lysine regulators in urological cancers is still unknown.
We first systematically analyzed the genetic and expression alterations of 31 lysine acetylation regulators in urological cancers. The correlation between lysine acetylation regulators and activation of cancer pathways was explored. The clinical relevance of lysine acetylation regulators was further analyzed.
We identified that there are widespread genetic alterations of lysine acetylation regulators, and that their expression levels are significantly associated with the activity of cancer hallmark-related pathways. Moreover, lysine acetylation regulators were found to be potentially useful for prognostic stratification. HDAC11 may act as a potential oncogene in cell cycle and oxidative phosphorylation of urological cancers.
Lysine acetylation regulators are involved in tumorigenesis and progression. Our results provide a valuable resource that will guide both mechanistic and therapeutic analyses of the role of lysine acetylation regulators in urological cancers.
赖氨酸乙酰化和去乙酰化是能够将细胞外信号与细胞内反应联系起来的翻译后修饰。然而，关于赖氨酸调节剂在泌尿系统癌症中的状态的知识仍然未知。
我们首先系统地分析了泌尿系统癌症中31种赖氨酸乙酰化调节剂的基因和表达改变。探讨了赖氨酸乙酰化调节剂与癌症通路激活之间的相关性。进一步分析了赖氨酸乙酰化调节剂的临床相关性。
我们发现赖氨酸乙酰化调节剂存在广泛的基因改变，并且它们的表达水平与癌症特征相关通路的活性显著相关。此外，发现赖氨酸乙酰化调节剂对预后分层可能有用。HDAC11可能在泌尿系统癌症的细胞周期和氧化磷酸化中作为潜在的癌基因起作用。
赖氨酸乙酰化调节剂参与肿瘤发生和进展。我们的结果提供了一个有价值的资源，将指导对赖氨酸乙酰化调节剂在泌尿系统癌症中的作用进行机制和治疗分析。
